ATYPICAL TERATOID/RHABDOID TUMOR
Clinical trials for ATYPICAL TERATOID/RHABDOID TUMOR explained in plain language.
Never miss a new study
Get alerted when new ATYPICAL TERATOID/RHABDOID TUMOR trials appear
Sign up with your email to follow new studies for ATYPICAL TERATOID/RHABDOID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise for rare childhood tumors
Disease control OngoingThis phase 2 trial is testing two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with rare INI1-negative cancers that have come back or not responded to treatment. The study aims to see if the combination can shrink tumors or slow disease progression.…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
New hope for young brain tumor patients: chemotherapy first, then targeted radiation
Disease control OngoingThis clinical trial tests a risk-adapted approach for young children with newly diagnosed brain tumors. The treatment starts with chemotherapy to delay radiation, giving the brain more time to develop. Then, radiation is carefully targeted to the tumor area to reduce side effects…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy targets rare childhood and adult cancers
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults with rare cancers that have come back or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to treat. The goal is to see if the drug com…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail targets childhood cancers with missing proteins
Disease control OngoingThis study tests a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—in children with rare tumors that lack the INI1 or SMARCA4 proteins. The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific tumor types are being…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Susan Chi, MD • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising drug targets rare childhood tumors in new trial
Disease control OngoingThis study tests a drug called alisertib in children and young adults (up to age 22) with rare, aggressive tumors called atypical teratoid rhabdoid tumors (AT/RT) in the brain or malignant rhabdoid tumors (MRT) elsewhere in the body. For patients whose cancer has come back or not…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells injected directly into brain show promise for kids with deadly tumors
Disease control OngoingThis early-phase study tests whether specially engineered immune cells (CAR T cells) can be safely given directly into the brain or spinal fluid of children and young adults with HER2-positive brain tumors that have come back or not responded to standard treatments. The therapy a…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New radiation technique aims to protect kids' bones and blood
Symptom relief OngoingThis study tests a special proton radiation method for children with brain tumors that need radiation to the brain and spine. The new approach spares parts of the backbone to reduce side effects like low blood counts and slowed bone growth. About 20 children aged 3 to 18 will rec…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC